Movement Alert｜Duality Biotherapeutics Rises 5.25% in Regular Trading, STAR Market IPO Progress and Sector Recovery Drive Rebound

Market Focus06-12 14:15

On June 12, Duality Biotherapeutics-B (mapped as DualityBio) rose 5.25% in regular trading, reaching HK$188.2 per share with turnover of HK$146 million, rebounding sharply from consecutive declines of 5.25% and 5.61% on June 8 and June 11 respectively.

On the news front, the company announced on June 10 that its STAR Market (Science and Technology Innovation Board) IPO guidance conducted by CITIC Securities has passed the verification by the Shanghai Bureau of the China Securities Regulatory Commission, marking a key milestone in its dual-listing strategy. This progress signals expanded capital market access and additional funding channels for its ADC pipeline development. Meanwhile, the company has maintained its buyback program, repurchasing 10,000 shares on June 10 at approximately HK$167.42 per share.

Within the Biotechnology sector, the overall tone turned positive. Among individual stocks, Remegen up 7.68%, Akeso up 5.58%, Innovent Bio up 4.46%, 3SBio up 2.89%, BeiGene up 1.42%, indicating a broad sector recovery from the prior session's collective selloff.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1187535832?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-12 14:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1187535832","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Duality Biotherapeutics Rises 5.25% in Regular Trading, STAR Market IPO Progress and Sector Recovery Drive Rebound","media":"Market Focus","content":"<p><p>On June 12, Duality Biotherapeutics-B (mapped as DualityBio) rose 5.25% in regular trading, reaching HK$188.2 per share with turnover of HK$146 million, rebounding sharply from consecutive declines of 5.25% and 5.61% on June 8 and June 11 respectively.</p><p>On the news front, the company announced on June 10 that its STAR Market (Science and Technology Innovation Board) IPO guidance conducted by CITIC Securities has passed the verification by the Shanghai Bureau of the China Securities Regulatory Commission, marking a key milestone in its dual-listing strategy. This progress signals expanded capital market access and additional funding channels for its ADC pipeline development. Meanwhile, the company has maintained its buyback program, repurchasing 10,000 shares on June 10 at approximately HK$167.42 per share.</p><p>Within the Biotechnology sector, the overall tone turned positive. Among individual stocks, Remegen up 7.68%, Akeso up 5.58%, Innovent Bio up 4.46%, 3SBio up 2.89%, BeiGene up 1.42%, indicating a broad sector recovery from the prior session's collective selloff.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Duality Biotherapeutics Rises 5.25% in Regular Trading, STAR Market IPO Progress and Sector Recovery Drive Rebound</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Duality Biotherapeutics Rises 5.25% in Regular Trading, STAR Market IPO Progress and Sector Recovery Drive Rebound\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-12 14:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 12, Duality Biotherapeutics-B (mapped as DualityBio) rose 5.25% in regular trading, reaching HK$188.2 per share with turnover of HK$146 million, rebounding sharply from consecutive declines of 5.25% and 5.61% on June 8 and June 11 respectively.</p><p>On the news front, the company announced on June 10 that its STAR Market (Science and Technology Innovation Board) IPO guidance conducted by CITIC Securities has passed the verification by the Shanghai Bureau of the China Securities Regulatory Commission, marking a key milestone in its dual-listing strategy. This progress signals expanded capital market access and additional funding channels for its ADC pipeline development. Meanwhile, the company has maintained its buyback program, repurchasing 10,000 shares on June 10 at approximately HK$167.42 per share.</p><p>Within the Biotechnology sector, the overall tone turned positive. Among individual stocks, Remegen up 7.68%, Akeso up 5.58%, Innovent Bio up 4.46%, 3SBio up 2.89%, BeiGene up 1.42%, indicating a broad sector recovery from the prior session's collective selloff.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09606","symbol_name":"映恩生物-B","start_time":0,"source_url":"","article_id":"1187535832","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1187535832","pubTimestamp":1781244931,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 12, Duality Biotherapeutics-B (mapped as DualityBio) rose 5.25% in regular trading, reaching HK$188.2 per share with turnover of HK$146 million, rebounding sharply from consecutive declines...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09606":"映恩生物-B"},"translate_title":"动向提示|Duality Biotherapeutics常规交易涨5.25%科创板IPO进展及板块复苏带动反弹","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09606":1},"content_text":"On June 12, Duality Biotherapeutics-B (mapped as DualityBio) rose 5.25% in regular trading, reaching HK$188.2 per share with turnover of HK$146 million, rebounding sharply from consecutive declines of 5.25% and 5.61% on June 8 and June 11 respectively.On the news front, the company announced on June 10 that its STAR Market (Science and Technology Innovation Board) IPO guidance conducted by CITIC Securities has passed the verification by the Shanghai Bureau of the China Securities Regulatory Commission, marking a key milestone in its dual-listing strategy. This progress signals expanded capital market access and additional funding channels for its ADC pipeline development. Meanwhile, the company has maintained its buyback program, repurchasing 10,000 shares on June 10 at approximately HK$167.42 per share.Within the Biotechnology sector, the overall tone turned positive. Among individual stocks, Remegen up 7.68%, Akeso up 5.58%, Innovent Bio up 4.46%, 3SBio up 2.89%, BeiGene up 1.42%, indicating a broad sector recovery from the prior session's collective selloff.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1187535832","isCrawlerRequest":true}